Deregulated methylation of cytosine in DNA is a frequent finding in malignancy that is reflected by general genomic hypomethylation and regional hypermethylation that includes the myogenic gene Myf-3. In this study of 198 DNA samples from 186 patients with a wide range of lymphoproliferative disorders (LPD), the methylation status of Myf-3 was assessed to evaluate its significance in the diagnosis of malignant LPD. DNA was digested with the restriction endonucleases HpaII and MspI, and using the Southern blot (SB) technique, the size and density of fragments that hybridized with a Myf-3 probe were used to assign the methylation status. None of the samples from 45 patients from a wide age range with benign LPDs had evidence of altered Myf-3 methylation and there was no age-related methylation change. By contrast, 115/123 (93%) of samples from patients with non-Hodgkin lymphoma (NHL) or lymphoid leukemia had increased Myf-3 methylation. There was no methylation alteration in 22/24 (92%) of samples from patients with Hodgkin lymphoma (HL), nor in five of six samples from LPDs that had atypical histopathologic features which were not diagnostic of lymphoma, while the remaining sample of atypical LPD had hypermethylated Myf-3 fragments. There was an association between increasing Myf-3 methylation and higher histopathologic grade of malignancy within specific lymphoma categories. It is concluded that the detection of increased Myf-3 methylation is a sensitive and specific test of malignancy which may complement other molecular methods that are currently used for the assessment of clonality. It may be of particular diagnostic use in natural killer (NK) and null cell malignancies for which other indicators of clonality are lacking. Furthermore, methylation status may prove to be of potential prognostic value. Leukemia (2001) 15, 583-589.
Introduction
The application of molecular techniques has greatly advanced the ability to distinguish between malignant and non-malignant lymphoproliferative disorders (LPDs). For example, Southern blotting (SB) and polymerase chain reaction (PCR)-based techniques are routinely used to detect monoclonal rearrangements of immunoglobulin (Ig) and T cell receptor (TCR) genes which in an appropriate clinical setting are characteristic of malignant LPDs. [1] [2] [3] Furthermore, some lymphoma categories have specific chromosomal translocations that occur at high frequency. However, these current markers of monoclonality have limited prognostic value and cannot be used to assess the clonality of NK and null cell proliferations where neither Ig or TCR genes are rearranged.
Cytosine methylation is a part of the heritable epigenetic machinery which is thought to influence cellular differen- tiation and proliferation by controlling gene expression. 4 Cytosine bases usually within a 5′ CpG 3′ dinucleotide are methylated by one or more of a series of 5-methyltransferase enzymes called DNMT1, 2, 3a and 3b. The activities of DNMT1, 3a and 3b for example, are increased in many types of neoplastic cells. 5, 6 Increased activity of the cytosine methylating systems in neoplastic cells is associated with hypermethylation of specific regions of the genome including the short arm of chromosome 11 7 which includes the myogenic gene Myf-3 8 (Myo-D1 9 ). Myf-3 is rich in 5′ CpG 3′ dinucleotides and it is hypomethylated in non-malignant cells. By contrast, in some types of neoplastic cells it has been shown to be hypermethylated. In our early studies we showed that Myf-3 is hypermethylated in DNA from a small number of malignant LPDs but not from benign LPDs. 10 Moreover, our investigations into the methylation status of Myf-3 in breast and colon neoplasms showed that it may be useful as a prognostic indicator. [11] [12] [13] This study of the methylation status of Myf-3 in DNA from benign and malignant lymphoid tissues from a large number of patients with a variety of LPDs was undertaken to determine its diagnostic significance in lymphoproliferative disorders.
Materials and methods

DNA isolation
Cases for study were selected retrospectively from archival freshly frozen lymphoid tissues or from EDTA anticoagulated peripheral blood leukocytes and bone marrow aspirates. All solid tissues were stored at −80°C prior to DNA extraction. DNA was isolated from each sample using a standard phenol/chloroform, ethanol precipitation method.
14 DNA was extracted from 198 samples from 186 patients with benign or malignant LPDs (one patient had metachronous NHL and HL). DNA samples were obtained from 134 lymph nodes, 11 splenic samples, eight peripheral blood leukocyte specimens, seven tonsils, six bone marrow aspirates, and 32 other extranodal tissues.
Case classification
Three groups of well-characterised cases of benign, malignant and atypical LPDs were used. Classifications were confirmed immunophenotypically and genotypically by PCR 1,2 and SB 3 based methods as previously described. The diagnosis of malignant B and T cell LPDs was supported by the detection of clonal antigen receptor gene rearrangements. Malignant LPDs were categorized according to the proposed WHO classification 15 (Table 1) . Follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL) samples were sub-grouped according to cytologic n, sample number, where multiple samples were examined from the same patient, patient numbers are given in square brackets. Two non-specific reactive hyperplasia samples had evidence of Epstein-Barr virus (EBV) infection using an in situ hybridization method. A further patient whose biopsy showed borderline histopathologic features of malignancy without evidence of clonality, later developed a NHL that had hypermethylation of Myf-3 (later sample not included Peripheral T cell lymphomas not otherwise characterized (PTL), were sub-grouped according to histopathologic grade of malignancy based on cell size. Lower grade PTL samples were composed of medium or mixed medium and large size cells, whereas higher grade PTL(l) samples were comprised predominantly of large cells.
The atypical LPD samples comprised five lymph nodes from five patients who had follicular hyperplasia with atypical histopathologic features that neither confirmed nor excluded a diagnosis of malignancy. In addition, there was a skin sample from a patient with lymphomatoid papulosis who had a lymphoid infiltrate with malignant cytological features that lacked immuno-or genotypic evidence of clonality. None of the atypical LPD samples had SB or PCR-based evidence of clonal antigen receptor gene rearrangements and none had clinical evidence of lymphoma subsequent to biopsy.
Influence of age
Several reports have shown that the methylation status of some regions of the genome changes with age. [16] [17] [18] [19] Consequently, studies were undertaken to determine whether the increased Myf-3 methylation associated with different types of LPD was attributable to malignancy or to the age of the patient.
Southern blotting
The methylation status of Myf-3 was determined as previously described. 10 Twelve g of DNA was digested to completion according to the manufacturer's instructions with 60 U of the methylation sensitive and insensitive isoschizomers HpaII and MspI, respectively. Following electrophoresis in a 1.8% agarose gel, the DNA was transferred to a positively charged nylon membrane using a BioRad (California, USA) vacuum blotter according to the manufacturer's instructions. DNA was hybridized with a 0.8 kb cDNA probe specific for the 3′ untranslated region of Myf-3 (ATCC 61522), radiolabelled by random priming to high specific activity with dCTP 32 P using a Rediprime labelling kit (Amersham, Bucks, UK) according to the manufacturer's instructions. Membranes were washed three times in a solution of 0.1% SDS and 0.1× SSC at 65°C for a total of 45-60 min. Autoradiograms were exposed at −80°C for a minimum of 2 days and fragment sizes were measured by reference to the electrophoretic mobility of DNA fragments obtained by the digestion of pUC 19 DNA with MspI and phage DNA with HindIII.
The largest detected fragment size, irrespective of density, was used to assign the extent of Myf-3 methylation.
Results
The results are summarised in Table 1 .
Benign LPD
Following HpaII digestion of genomic DNA from benign LPDs, the Myf-3 probe hybridized to two major fragments of approximately 0.6 kb and 0.4 kb. In most samples the density of the 0.4 kb fragment was greater than or equal to the density of the 0.6 kb fragment. In nine of the 45 samples (20%), the 0.6 kb fragment was slightly denser than the 0.4 kb fragment. Two additional, weakly hybridizing fragments of approximately 0.2 kb were detected in all samples. MspI digests of benign and malignant samples consistently produced the two fragments of approximately 0.2 kb and the single band of 0.4 kb which were also detected in HpaII digests. As shown in Figure 1 , the size of each of the MspI digested Myf-3 hybridizing fragments was predicted from the published sequence of Myf-3. 8 Based on these findings, hypermethylation of Myf-3 was assigned by the presence of fragments larger than 0.8 kb in size. By contrast, a minor increase of Myf-3 methylation was
Figure 1
The MspI restriction sites (M) and predicted fragment sizes that hybridize to the Myf-3 probe are shown 8 (GenBank accession number AF027148). These fragment sizes were similar to the observed sizes in MspI digested DNA. Methylation at the indicated restriction site (↓) was predicted to result in a hybridizing fragment of approximately 0.6 kb in HpaII digested DNA. The cleavage site within the 5′ CCGG 3′ recognition sequences M 1 to M 7 , is immediately 3′ of the cytosine indicated by the nucleotide sequence number 11917, 12099, 12488, 12498, 12533, 12583 and 12795, respectively. Leukemia assigned if there was an absent or weakly hybridizing 0.4 kb fragment relative to the density of the 0.6 kb fragment and/or by the presence of relatively dense fragments larger than 0.6 kb and up to 0.8 kb in size that were absent in DNA from benign lymphoid tissues. According to these criteria there was no evidence of altered methylation in any of the benign LPD samples, including two hyperplastic EBV-positive DNA samples which had Myf-3 fragments of size and relative density that were indistinguishable from those of the other benign samples. Moreover, there was no evidence of tissue-specific methylation when the findings were compared of samples of peripheral blood leukocytes from healthy donors (results not shown), or lymph nodes, tonsils or spleens from patients with benign LPD.
LPD with atypical histopathologic features
Of the five samples of DNA from lymph nodes of patients diagnosed with atypical follicular hyperplasia, one sample had an intense Myf-3 hybridizing fragment of 1.0 kb and a weakly hybridizing Myf-3 fragment of 1.2 kb. The DNA sample of the skin biopsy from the patient who had lymphomatoid papulosis had no evidence of increased Myf-3 methylation.
Non-Hodgkin lymphoma and lymphoid leukemia
Myf-3 was hypermethylated in 73 of the 92 (79%) samples of DNA from patients diagnosed with malignant B cell LPD. Myf-3 was also hypermethylated in 16/27 (59%) of DNA samples from patients diagnosed with malignant T cell LPD and the three DNA samples from patients with malignant NK/T cell LPD (Figures 2 and 3) . Of the 120 DNA samples from patients who had malignant LPD (excludes three repeat DNA samples that had the same maximum-sized Myf-3 hybridizing fragment in DNA from the first and subsequent biopsies), 30 had no evidence of Myf-3 hypermethylation. Of these, 22 DNA samples which included the DNA sample from a patient diagnosed with null cell ALCL, had evidence of a minor increase of Myf-3 methylation (Table 1) . Comparison of the median Myf-3 hybridizing fragment size in samples of NHL/leukemia (1.8 kb) vs benign LPD samples (0.6 kb) showed a statistically significant increased level of Myf-3 methylation in the malignant samples (P Ͻ 0.0001). The number of Myf-3 fragments indicated that not all the cells within a clone had identical sites of methylation and were polyclonal with respect to their level of increased methylation (Figure 3 ). This finding was in contrast to the evidence of monoclonal Ig or TCR gene rearrangements (Figure 4) .
Comparison of the median Myf-3 fragment size in DNA samples of FL, DLBCL and PTL that were sub-grouped according to low or high histopathologic grade of malignancy, showed a significantly greater level of methylation in FL and PTL lymphomas of higher histopathologic grade (Table 2 and Figures 5 and 6 ). By contrast, there was no statistically significant methylation difference in the sub-groups of DLBCL.
No evidence of deregulated Myf-3 methylation was found in DNA samples from eight patients (all had a sufficient number of clonal cells to be detected by SB using antigen receptor gene probes) (Figure 4) . The overall failure rate to detect increased methylation of Myf-3 in patients with NHL/leukemia was 8/113 (7%). 
Hodgkin lymphoma
There was no evidence of altered Myf-3 methylation in DNA samples from 22/23 patients (including one sample with evidence of EBV infection using an in situ hybridization technique). Hypermethylated Myf-3 fragments were seen in two metachronous DNA samples from a patient with mixed cellularity HL in which the later sample had evidence of a clonal T cell population. The earlier DNA sample had a maximum-sized Myf-3 fragment of 1.2 kb and the later 3.1 kb. These fragments were faint by comparison with the 0.4 kb band and indicated that only a small proportion of cells had hypermethylated Myf-3 ( Figure 3 ).
Influence of age on Myf-3 methylation
In order to determine whether the methylation status of Myf-3 in DNA from lymphoid cells varied with age, the maximum extent of Myf-3 methylation was compared in DNA from tissue samples of lymph node, tonsil and spleen from patients of a wide age range that were diagnosed with benign LPD. The maximum fragment size ranged from 0.5 kb to less than 0.8 kb throughout the age groups sampled and there was no increase in the methylation status of Myf-3 with age.
Discussion
Deregulated DNA methylation is a frequent finding in malignancy and previous studies of DNA from colon, breast and lymphoid tissues showed that the Myf-3 gene is hypermethylated in malignant but not benign tissues. [10] [11] [12] [13] Myf-3 has not been shown to be expressed in normal, benign or malignant lymphoid tissues and there is no in vivo evidence to indicate Southern blot showing clonally rearranged fragments of DNA from NHL hybridizing with antigen receptor gene probes. An immunoglobulin heavy chain joining region probe was hybridized to EcoR1 (lane 1) and HindIII (lane 2) digested DNA from the patient with splenic marginal zone B cell lymphoma without unequivocal evidence of increased Myf-3 methylation (Figure 2, lane 13) . Both digests clearly indicate a monoclonal cell population which has rearranged both alleles. Comparison of germline and rearranged fragment densities indicates that the proportion of clonal cells is less than 50%. A kappa light chain joining region probe was hybridized to EcoRI (lanes 3, 4) and HindIII (lanes 5, 6) digested DNA from a patient with diffuse large B cell lymphoma having pleomorphic cytology (lanes 4, 6) and placenta from a healthy donor (lanes 3, 5). Both kappa alleles of the lymphoma sample are rearranged and the relative density of the rearranged and germline fragments indicates a very high proportion of clonal cells which is consistent with the relative density of the hypermethylated Myf-3 fragments in the Myf-3 Southern blot ( Figure 3, lane 4) . Bars indicate germline fragments and arrows indicate clonally rearranged fragments.
Table 2
Comparison of maximum Myf-3/HpaII fragment sizes between categories of non-Hodgkin lymphoma/leukemia having different histopathologic grades of malignancy n, sample number, excluding repeat samples (3) having the same maximum fragment size. Fisher's exact test (two-sided) was used to compare the frequency of fragments Ͼ0.8 kb in the PTL and PTL(l) samples. All other statistical analyses used the Mann-Whitney test (two-sided) to compare the median Myf-3 fragment sizes.
that Myf-3 methylation contributes to lymphomagenesis, thus the biological significance of Myf-3 hypermethylation in malignant LPDs remains unclear. However, the chromosomal location and the density of CpG dinucleotides in Myf-3 indicated that it may have the potential to be a sensitive marker of deregulated DNA methylation in lymphomas.
The finding of increased Myf-3 methylation in samples from 93% of patients with NHL/leukemia but not in any samples from patients with benign LPDs indicates that the methylation status of Myf-3 is a sensitive and specific marker of malignancy. Importantly, it may serve as a surrogate marker of clonality in NK and null cell proliferations for which the assessment of antigen receptor gene rearrangements is uninformative.
The highly variable level of increased Myf-3 methylation found in many of the NHL/leukemia categories was consistent
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Figure 5
Plot depicting the maximum Myf-3 fragment size in HpaII digests of DNA from B cell malignancies using Southern blotting. The wide range of values within many categories reflects their heterogeneous nature. Hypermethylated fragments were absent in some samples; however, the majority of these had a minor increase of methylation that was absent in benign LPDs. FL and DLBCL were subgrouped according to histopathologic criteria that reflected malignancy grade, those FL comprised of predominantly large cells (grade 3) with or without diffuse growth more frequently had more extensive Myf-3 methylation than those without. Consistent with its low grade, DNA from samples of B-SLL had a uniformly low level of increased methylation which was distinct from that seen in benign LPDs. B-SLL: B cell small lymphocytic lymphoma (10); PC: plasma cell myeloma (2); B-PLL: B cell prolymphocytic leukemia (1); MCL: mantle cell lymphoma (10); aBL: atypical Burkitt lymphoma (3); FL: follicular lymphoma; small cleaved cell or mixed small and large cell with follicular growth (26); FL(l/d): follicular lymphoma, grade 3 with or without diffuse growth (6); DLBCL: diffuse large B cell lymphoma, unspecified cytology (9); DLBCL(p/i): diffuse large B cell lymphoma, pleomorphic or immunoblastic cytology (8); MZL: marginal zone lymphoma, MALT type (7), splenic type (1), nodal type (1); and B-LBL: precursor B lymphoblastic leukemia/lymphoma (6) . The number of samples is indicated and excludes two repeat samples of FL from one patient in which all samples had an identical maximum fragment size.
with their clinically and histopathologically heterogeneous nature (Figures 5 and 6 ). Nevertheless, some categories had a level of increased methylation consistent with their histopathologic grade of malignancy which might indicate a potential value for Myf-3 methylation status in prognostication. In addition, the high frequency of increased Myf-3 methylation in NHL/leukemia and its absence in benign LPDs supports the notion that deregulated methylation is more likely to be an early event in lymphomagenesis.
By contrast to the findings in NHL, increased Myf-3 methylation was infrequently detected in DNA from the samples harboring HL. This may be due to the generally small proportion of malignant cells in HL that is below the limit of detection using the Southern blot technique, or alternatively, increased methylation may not be a feature of the malignant cells of HL. The significance of the coincidental findings of Plot depicting the maximum Myf-3 fragment size in HpaII digests of DNA from T and NK/T cell malignancies using Southern blotting. Similar to the findings in B cell malignancies there is a wide range of values ( Figure 5 ). DNA from samples of T-LBL had a greater level of hypermethylation when compared with other malignancies and reflected the highly malignant nature of this disease. DNA from samples of PTL(l) had greater hypermethylation than PTL and is consistent with the relatively higher histopathologic grade of malignancy of PTL that are composed of large cells. The two samples of HSL were from one patient, an initial sample of splenic tissue had a minor increase of Myf-3 methylation, by comparison, a sample of leukemic lymphocytes taken 4 years later had hypermethylation of Myf-3 which is consistent with de novo methylation. Similar to the B cell malignancies, DNA from some T and T/NK malignancies did not have hypermethylated Myf-3. T-PLL: T cell prolymphocytic leukemia (1); T-GLL: T cell granular lymphocytic leukemia (3); NK/T, n: extranodal NK/T cell lymphoma, nasal type (2); UNK: unclassified high grade cutaneous NK cell lymphoma (1); HSL: hepatosplenic ␥␦ T cell lymphoma (2); SS: Sezary syndrome (1); PTL: peripheral T cell lymphoma, not otherwise characterized, medium cell or mixed medium and large cell (4); PTL(l): peripheral T cell lymphoma, not otherwise characterized, large cell (5); ALCL: anaplastic large cell lymphoma, primary systemic type, CD30 positive (4); and T-LBL: precursor T lymphoblastic leukemia/lymphoma (7) . The number of samples is indicated and excludes a repeat sample from one patient with T-GLL that had a constant maximum fragment size.
Myf-3 hypermethylation and T cell clonality in one sample of HL is unclear. Clonal TCR␥ gene rearrangements have been reported rarely in HL but without clear evidence to identify the malignant cells of HL as having the clonal rearrangement. 20 One possibility is that this sample had clonal cells with both hypermethylated Myf-3 and clonally rearranged TCR␥ genes and that these cells were in sufficient number for the hypermethylated Myf-3 to be detected by the Southern blot method. These clonal cells might be the malignant cells of HL or a predominant clone of benign, reactive T lymphocytes with uncharacteristic Myf-3 hypermethylation.
The finding of hypermethylated Myf-3 fragments was unexpected in a sample from a patient who had an atypical LPD that had no phenotypic or genotypic evidence of clonality. The DNA sample from the patient who had lymphomatoid papulosis did not have evidence of increased Myf-3 methylation and was consistent with the lack of detectable clonal gene rearrangements but not with the malignant cytological appearance of the abnormal lymphocytes. Interestingly, a proportion of patients with lymphomatoid papulosis have disease progression to cutaneous ALCL and in three of four ALCL samples there was increased Myf-3 methylation (Figure 6 ). These findings raise the possibility that deregulation of the DNA methylating machinery is a contributory factor in disease progression.
The effect of EBV infection on Myf-3 methylation in LPDs remains to be studied. However, in the three EBV infected samples tested, there was no evidence of increased Myf-3 methylation suggesting that EBV infection in the absence of malignancy is not sufficient to induce increased methylation of Myf-3.
In conclusion, this study of the level of Myf-3 methylation in a large number of benign and malignant LPDs shows that it is a sensitive diagnostic test for the detection of malignant lymphoid cells and is especially useful in those cases in which current molecular diagnostic methods are unhelpful. Furthermore, in some categories of NHL/leukemia the association of the level of Myf-3 methylation with the histopathologic grade of malignancy has potential value as an aid in prognostication.
